Clinical Trials Directory

Trials / Completed

CompletedNCT03956212

Inflammatory Mediators in Erythema Migrans

Inflammatory Proteins, Gene Polymorphisms, and Transcriptome Profiles in Patients With Erythema Migrans

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
150 (actual)
Sponsor
University Medical Centre Ljubljana · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The main objective of this study is to characterize the inflammatory proteins, gene polymorphisms, and transcriptome profiles in patients with erythema migrans to gain better insight into pathogenesis of early Lyme borreliosis and to define new immune modulators that could serve as biomarkers of disease activity.

Conditions

Interventions

TypeNameDescription
DRUGDoxycycline 7 daysPatient will be treated with doxycycline orally, 100 mg, bid, 7 days
DRUGDoxycycline 14 daysPatient will be treated with doxycycline orally, 100 mg, bid, 14 days

Timeline

Start date
2017-06-01
Primary completion
2019-12-31
Completion
2020-10-31
First posted
2019-05-20
Last updated
2020-11-03

Locations

1 site across 1 country: Slovenia

Source: ClinicalTrials.gov record NCT03956212. Inclusion in this directory is not an endorsement.

Inflammatory Mediators in Erythema Migrans (NCT03956212) · Clinical Trials Directory